Houston, TX, United States of America

Long Vien

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: The University of Texas System. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Long Vien. Retrieved from https://idiyas.com/inventor/long-vien

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Long Vien: Innovator in Antibody Research

Introduction

Long Vien is a notable inventor based in Houston, Texas. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. His work is recognized for its potential impact on medical research and therapeutic applications.

Latest Patents

Long Vien holds a patent for "ANTI-BST2 ANTIBODIES TARGETING BST2 LONG ISOFORM." This innovative patent showcases his expertise in antibody development and its implications for disease treatment.

Career Highlights

Long Vien is affiliated with The University of Texas System, where he engages in cutting-edge research. His role at the university allows him to collaborate with other experts in the field and contribute to advancements in biotechnology.

Collaborations

One of his notable collaborators is Felipe Amaya-Manzanares. Together, they work on projects that aim to enhance the understanding and application of antibody technologies.

Conclusion

Long Vien's contributions to antibody research exemplify the innovative spirit of modern science. His work continues to pave the way for future advancements in medical therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…